Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Alzheimer's disease drug research most recently characterized by setbacks, not breakthroughs, the field is shifting toward a biomarker-based approach that will allow for the treatment of patients earlier in the course of the disease – before they show symptoms.